ClinicalTrials.gov
ClinicalTrials.gov Menu

Ticagrelor and Peripheral Arterial Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02407314
Recruitment Status : Terminated (AZ discontinued study)
First Posted : April 2, 2015
Last Update Posted : June 27, 2018
Sponsor:
Collaborators:
The University of Texas Health Science Center at San Antonio
University of Alabama at Birmingham
Information provided by (Responsible Party):
Arkansas Heart Hospital

Brief Summary:
This is an interventional study assessing the effectiveness of Ticagrelor on the reduction of thrombus burden using optical coherence tomography in patients undergoing peripheral artery stenting.

Condition or disease Intervention/treatment Phase
Peripheral Arterial Disease Procedure: Percutaneous Peripheral Intervention Device: Optical Coherence Tomography Other: Ankle Brachial Index Other: Six minute walk distance Drug: Aspirin Drug: Aspirin + Ticagrelor Phase 4

Detailed Description:

Prospective, randomized study, comparing ticagrelor + aspirin vs. aspirin monotherapy following the 4-week post-procedural combination of Ticagrelor or Plavix with low dose aspirin. The investigators will enroll a minimum of 40 patients. Patients will be enrolled if they have either claudication and/or critical limb ischemia, and angiographically identified superficial femoral artery (SFA) disease requiring intervention, with either total occlusion or a significant SFA stenosis with the presence of Optical Coherence Tomography (OCT) defined clot following stent placement.

Participants will be evaluated at baseline, 1 month, 4 months, 6 and 7 months following SFA intervention. At baseline demographic data will be collected, and anthropomorphic and physiological variables (body mass index, waist circumference, blood pressure). Baseline and 6-month ankle brachial index (ABI) will be performed. A 6-min walk test will be performed at baseline and 6-month follow-up. At 6 month time point patients in both treatment groups will return for a peripheral angiogram and repeat OCT imaging of the SFA segments of interest. Subject will have a final follow up clinic visit at 7 months.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Impact of Ticagrelor and Aspirin Versus Clopidogrel and Aspirin in Patients With Claudication and Peripheral Arterial Disease (PAD): Thrombus Burden Assessed by Optical Coherence Tomography
Study Start Date : June 2015
Actual Primary Completion Date : January 17, 2017
Actual Study Completion Date : January 17, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Sham Comparator: Aspirin only
Clopidogrel 75 mg + aspirin 81 mg for the first month followed by aspirin 81 mg alone for months 2-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT) ankle brachial index (ABI) and six minute walk distance.
Procedure: Percutaneous Peripheral Intervention
Percutaneous peripheral intervention is a common procedure performed by cardiologists to revascularize peripheral arterial lesions in patients (stent placement). This procedure is considered standard of care and is not experimental.

Device: Optical Coherence Tomography
This is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media. The device used is a cardiac catheter with OCT sensors on the tip of it. It will be used to assess the artery vessels after Percutaneous Peripheral Intervention.

Other: Ankle Brachial Index
This a clinical assessment and consists of the calculation of the ratio of the blood pressure in the lower legs to the blood pressure in the arms. The ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm.

Other: Six minute walk distance
Assessment of the walking distance in 6 minutes.

Drug: Aspirin
Aspirin, also known as acetylsalicylic acid [ASA], is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels.
Other Name: Acetylsalicylic acid [ASA]

Experimental: Aspirin + Ticagrelor
ticagrelor 90 mg bid + aspirin 81 mg for months 1-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT)ankle brachial index (ABI) and six minute walk distance.
Procedure: Percutaneous Peripheral Intervention
Percutaneous peripheral intervention is a common procedure performed by cardiologists to revascularize peripheral arterial lesions in patients (stent placement). This procedure is considered standard of care and is not experimental.

Device: Optical Coherence Tomography
This is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media. The device used is a cardiac catheter with OCT sensors on the tip of it. It will be used to assess the artery vessels after Percutaneous Peripheral Intervention.

Other: Ankle Brachial Index
This a clinical assessment and consists of the calculation of the ratio of the blood pressure in the lower legs to the blood pressure in the arms. The ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm.

Other: Six minute walk distance
Assessment of the walking distance in 6 minutes.

Drug: Aspirin + Ticagrelor
This is a combination of drugs (Aspirin + Ticagrelor). Ticagrelor is a platelet aggregation inhibitor due to its properties as an antagonist of the P2Y12 receptor. Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall similarity to adenosine.
Other Name: acetylsalicylic acid [ASA] + Brillinta




Primary Outcome Measures :
  1. Change in the Intraluminal clot volume (in mm3) and length (mm) at 6 months [ Time Frame: At baseline and at 6 months ]
    Intraluminal clot volume and length will be assessed by Optical Coherence Tomography using a Core Lab.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with lower extremity claudication and PAD due to significant SFA stenosis (>60%) or total occlusions (Rutherford 2-6) that affects the quality of life despite medical therapy.
  • The presence of OCT identified clot in the Superficial Femoral Artery (SFA) following stent placement.
  • Evidence of significant SFA disease involving the most symptomatic limb established by noninvasive vascular testing (ankle-brachial index [ABI] <0.9, toe brachial Index [TBI] of <0.6. If ABI>1.4, SFA systolic acceleration time >140 milliseconds); computed tomographic angiography, or magnetic resonance angiography confirming at least a 60% stenosis of the SFA.
  • At least one non-treated Below The Knee (BTK) vessel patent
  • Male and female outpatients 18 years of age.
  • The only following devices may be used for the revascularization procedures: conventional balloons and bare metal stents (block randomization).
  • Subject has been advised of the beneficial effects of smoking cessation and regular exercise but must not be in the process of changing their smoking status at the time of screening. Patients may resume or increase exercising as an effect of post procedurally improved lower limb perfusion.
  • Peak Walking Time (PWT) limited only by claudication.
  • Willingness to participate, documented by written informed consent.

Exclusion Criteria:

  • Patients requiring dual anti-platelet drug treatment before start of study
  • Planned amputation
  • Use of atherectomy devices
  • Hypersensitivity to acetylsalicylic acid, or ticagrelor. For ticagrelor, hypersensitivity reactions in the past include angioedema
  • Patients with known bleeding disorders
  • Patients with known active pathological bleeding
  • Patients needing chronic oral anticoagulant maintenance therapy
  • Patients with a history of intracranial hemorrhage at any time, GI bleed in the past 6 months, or major surgery within the past 30 days
  • Ischemic stroke during the past 3 months
  • Patients considered to be at risk of bradycardic events unless treated with a permanent pacemaker
  • Target is a restenotic lesion or in-stent restenosis
  • Any scheduled revascularization procedure requiring dual-anti-platelet therapy for more than one month
  • Severe hypertension that may put the patient at risk, systolic greater than or equal to 180 and/or diastolic greater than or equal to 100
  • Severe liver disease
  • History of congestive heart failure with an Left Ventricular Ejection Fraction (LVEF) of less than 30%
  • Concern for inability of the patient to comply with study procedures and/or follow up (eg, alcohol or drug abuse)
  • Infra-popliteal disease involving the last remaining vessel (single run-off)
  • Prior lower extremity revascularization within the past 30 days prior to enrollment
  • Atherectomy of PAD
  • EXCIPIENTS to ticagrelor hypersensitivity
  • Known pregnancy, breast-feeding, or intend to become pregnant during the study period (all female patients 55 years and younger, without past history of hysterectomy must have a pregnancy test prior to peripheral intervention at baseline and at 6 months)
  • Creatinine clearance < 30 mL/min

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02407314


Locations
United States, Arkansas
Arkansas Heart Hospital
Little Rock, Arkansas, United States, 72211
Sponsors and Collaborators
Arkansas Heart Hospital
The University of Texas Health Science Center at San Antonio
University of Alabama at Birmingham
Investigators
Principal Investigator: Mehmet Cilingiroglu, MD Arkansas Heart Hospital
Principal Investigator: Massoud Leesar, MD University of Alabama at Birmingham
Principal Investigator: Hinan Ahmed, MD University Of Texas Health Science Center in San Antonio
Principal Investigator: Marc D Feldman, MD University Of Texas Health Science Center in San Antonio
Study Director: Gerardo Rodriguez, MD PhD Arkansas Heart Hospital

Responsible Party: Arkansas Heart Hospital
ClinicalTrials.gov Identifier: NCT02407314     History of Changes
Other Study ID Numbers: ESR-14-10020
First Posted: April 2, 2015    Key Record Dates
Last Update Posted: June 27, 2018
Last Verified: March 2017

Keywords provided by Arkansas Heart Hospital:
Peripheral Arterial Disease
Optical Coherence Tomography
Ticagrelor
Aspirin
Claudication
Clopidogrel

Additional relevant MeSH terms:
Peripheral Arterial Disease
Peripheral Vascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Aspirin
Clopidogrel
Ticagrelor
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents